Advertisement

Table of Contents

August 16, 2018; 132 (7)

BLOOD COMMENTARIES

PERSPECTIVE

BLOOD SPOTLIGHT

CLINICAL TRIALS AND OBSERVATIONS

  • Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
    Edit Porpaczy, Sabrina Tripolt, Andrea Hoelbl-Kovacic, Bettina Gisslinger, Zsuzsanna Bago-Horvath, Emilio Casanova-Hevia, Emmanuelle Clappier, Thomas Decker, Sabine Fajmann, Daniela A. Fux, Georg Greiner, Sinan Gueltekin, Gerwin Heller, Harald Herkner, Gregor Hoermann, Jean-Jacques Kiladjian, Thomas Kolbe, Christoph Kornauth, Maria-Theresa Krauth, Robert Kralovics, Leonhard Muellauer, Mathias Mueller, Michaela Prchal-Murphy, Eva Maria Putz, Emmanuel Raffoux, Ana-Iris Schiefer, Klaus Schmetterer, Christine Schneckenleithner, Ingrid Simonitsch-Klupp, Cathrin Skrabs, Wolfgang R. Sperr, Philipp Bernhard Staber, Birgit Strobl, Peter Valent, Ulrich Jaeger, Heinz Gisslinger and Veronika Sexl
  • Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP)
    Hervé Decousus, Aurélie Bourmaud, Pierre Fournel, Laurent Bertoletti, Carine Labruyère, Emilie Presles, Adel Merah, Silvy Laporte, Laetitia Stefani, Francesco Del Piano, Jean-Philippe Jacquin, Guy Meyer and Franck Chauvin for the ONCOCIP Investigators
  • Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia
    Thomas W. LeBlanc, Pamela C. Egan and Adam J. Olszewski

LYMPHOID NEOPLASIA

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

LETTERS TO BLOOD

BLOOD WORK

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS